TrialThe Journal of antimicrobial chemotherapy2024

A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia.

Anne-Marie Chaftari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.